A major problem in cancer treatment is the development of resistance to multiple chemotherapeutic agents in tumor cells. A major mechanism of this multidrug resistance (MDR) is overexpression of the MDR1 product P-glycoprotein, known to bind to and transport a wide variety of agents. This review concentrates on the progress made toward understanding the role of this protein in MDR, identifying and characterizing the drug binding sites of P-glycoprotein, and modulating MDR by P-glycoprotein-specific inhibitors. Since our initial discovery that P-glycoprotein binds to vinblastine photoaffinity analogs, many P-glycoprotein-specific photoaffinity analogs have been developed and used to identify the particular domains of P-glycoprotein capable of interacting with these analogs and other P-glycoprotein substrates. Furthermore, significant advances have been made in delineating the drug binding sites of this protein by studying mutant P-glycoprotein. Photoaffinity labeling experiments and the use of site-directed antibodies to several domains of this protein have allowed the localization of the general binding domains of some of the cytotoxic agents and MDR modulators on P-glycoprotein. Moreover, site-directed mutagenesis studies have identified the amino acids critical for the binding of some of these agents to P-glycoprotein. Furthermore, equilibrium binding assays using plasma membranes from MDR cells and radioactive drugs have aided our understanding of the modes of drug interactions with P-glycoprotein. Based on the available data, a topological model of P-glycoprotein and the approximate locations of its drug binding sites, as well as a proposed classification of multiple drug binding sites of this protein, is presented in this review.
[1]
H. Fujita.
[Anticancer drugs].
,
1995,
Nihon rinsho. Japanese journal of clinical medicine.
[2]
R. Koff.
Multidrug resistance in cancer cells: Biochemical mechanisms
,
1989
.
[3]
Mark J. Ratain,et al.
Principles of Antineoplastic Drug Development and Pharmacology
,
1996
.
[4]
R. Ozols.
Molecular and Clinical Advances in Anticancer Drug Resistance
,
2012,
Cancer Treatment and Research.
[5]
I. Pastan,et al.
Characterization of the azidopine and vinblastine binding site of P-glycoprotein.
,
1992,
The Journal of biological chemistry.
[6]
P. Houghton,et al.
Preclinical and Clinical Modulation of Anticancer Drugs
,
1993
.